Daix (France), New York City (New York, United States), July 9, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ('Inventiva” or the 'Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the 'Combined Transaction”) through the issuance of approximately 15.7 million new warrants (bons de souscription d’actions) (the 'New EIB Warrants') to the European Investment Bank (the 'EIB') and the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 (the 'Legacy EIB Tranche B Warrants”) that were not repurchased in the Combined Transaction.